| Identification | More | [Name]
6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine | [CAS]
88965-00-8 | [Synonyms]
6-METHYL-2-P-TOLYL-IMIDAZO[1,2-A]PYRIDINE
6-methyl-2-(4-methylphenyl)imidazo[1,2-alpha]pyridine
6-Methyl-2-(4-methylphenyl-imidazo[1,2-a]pyridine
ZolpidemTartrate1.6-Methyl-2-(4-Methylphenyl)Imidazo[1,2-A]Pyridine
IMIDAZO[1,2-A]PYRIDINE, 6-METHYL-2-(4-METHYLPHENYL)-
6-METHYL-2-P-TOLY-IIDAZOLE(1,2)PYRIDINE | [Molecular Formula]
C15H14N2 | [MDL Number]
MFCD00444739 | [Molecular Weight]
222.29 | [MOL File]
88965-00-8.mol |
| Hazard Information | Back Directory | [Uses]
6-Methyl-2-(4-methylphenyl)-imidazo[1,2-a]pyridine is an impurity of Zolpidem (Z650000), a selective non-benzodiazepine GABAA receptor agonist. | [Biological Activity]
O4I3 is a highly potent and KDM5A (JARID1A) subtype-selective H3K4 demethylase KDM5 inhibitor (KDM5A IC50 = 0.15 nM vs KDM5B/C/D IC50 = 125.2/9.76/4.7 nMKDM4 IC50 = 249 nMLSD1 IC50 >100 μM) th at effectively induces OCT4 expresson and improves OSKM-induced pluripotent stem cell (iPSC) reprogramming efficiency of human primary fibroblasts (50 nM) by preventing KDM5A from interfering with H3K4Me3 enrichment at the OCT4 promoter. O4I3 promotes hPSC homeostasis and represses cellular differentiationincreasing hPSCs viability up to 4-fold at a low 10 nM concentration when compared with Rock inhibitor Y-27632 treatment at 10 μM. |
|
|